Innovation-Driven

  • In 2022

    104 billion11

    R&D investment reached

    (RMB)

  • 1771

    授权发明专利

  • 10 +

    Global technology innovation centers

  • Leading Core technologies in various fields

    Innovative drug:focus on therapeutic areas such as oncology,immunology, central nervous system, and chronic disease, and mainly strengthencore technology platforms such as small molecule, antibody/ADC, cell therapy,and RNA

    Vaccine: platforms of bacterial vaccine + viral vaccine

    Device: three major platforms of medical cosmetology +respiratory health + professional medical care

    Research & application of OrientalLifestyle Aesthetics

    Construction of the 4D technology innovation system: five senses ofconsumers + technology innovation R&D + creative design + technologyinnovation digitalization

    Insurance: digital platformoptimizes customer experience throughout the life cycle

    Intelligent travel: full-stack self-developed L2+ intelligentdriving software and hardware solutions

    Industrial automation: leveraging digital twin, machine vision andother technologies accumulated for many years in the industry, AIGC largemodels are introduced to promote full intelligence and automation in theindustry

    New energy: from traditional energy to the upstreamextension of new energy and new materials

  • Technology innovation centers in various fields

    Fosun Pharma Global R&D Center (national level)

    JEVE Technology Center (national level)

    Wanbang Biopharma Quality Department QC Lab2 (CNAScertified)

    Fosun Cosmetics Global Innovation Center2

    Fosun Pharma North America R&D Headquarters

    Shanghai Key Laboratory of Stem Cell Therapy

    Sichuan Engineering Technology Center for IntelligentBrewing of Baijiu

    Lanvin Group Design Center in Milan, Italy and the UK

    Yuyuan Jewelry Creative House

    Yuyuan Foods & Dining Group Innovation Center Base

    Academician Enterprise Research Institute

    ……

1It includes scientific research investment (expensed and capitalized), but excludes digitalization expenses.
2Application of CNAS (China National Accreditation Service for Conformity Assessment) certified laboratory is in progress

  • 13价肺炎球菌结合疫苗

    于中国境内(不包括港澳台地区)处于III期临床阶段

  • HANSIZHUANG (serplulimab injection)

    Self-developed biopharmaceutical innovative drug and the world's first monoclonal antibody drug targeting PD-1 for first-line treatment of extensive-stage small cell lung cancer
    Approved for three indications in China (excluding Hong Kong, Macau and Taiwan regions)

  • Yi Kai Da (ejilunsai injection)

    国内第1个获批上市的CAR-T细胞治疗产品
    用于二线治疗成人大B细胞淋巴瘤的上市注册申请于中国境内(不包括港澳台地区)获受理并纳入优先审评

  • 愈感

    第一个自主研发的面向敏感肌护肤品品牌-愈感问世

  • 舍得酒业

    攻关“保持基酒老酒特征的特制新材料升级处理基酒”技术方案

  • 葡萄牙保险

    My Fidelidade APP注册用户数突破100万,APP端就诊报销占比>46%,车险数字化理赔占比>48%

  • 复睿智行

    发布高性能4D毫米波雷达为核心的融合感知方案

  • 翌耀科技

    自主研发的新能源系统装备首次交付海外大客户

  • 海南矿业

    投资建设的2万吨氢氧化锂项目(一期)已正式动工,并正在积极推进非洲马里Bougouni锂矿的并购和开发

x

抖音二维码

扫一扫